Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Fundamental Analysis

NASDAQ:CADL - Nasdaq - US1374041093 - Common Stock - Currency: USD

11.63  -0.58 (-4.75%)

After market: 11.75 +0.12 (+1.03%)

Fundamental Rating

1

Taking everything into account, CADL scores 1 out of 10 in our fundamental rating. CADL was compared to 571 industry peers in the Biotechnology industry. CADL may be in some trouble as it scores bad on both profitability and health. CADL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CADL had negative earnings in the past year.
CADL had a negative operating cash flow in the past year.
In the past 5 years CADL always reported negative net income.
In the past 5 years CADL always reported negative operating cash flow.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -92.10%, CADL is doing worse than 72.65% of the companies in the same industry.
The Return On Equity of CADL (-297.72%) is worse than 75.31% of its industry peers.
Industry RankSector Rank
ROA -92.1%
ROE -297.72%
ROIC N/A
ROA(3y)-52.25%
ROA(5y)-44.18%
ROE(3y)-131.12%
ROE(5y)-96.56%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

CADL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

3

2. Health

2.1 Basic Checks

CADL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CADL has more shares outstanding
The debt/assets ratio for CADL is higher compared to a year ago.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 4.32 indicates that CADL is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.32, CADL is doing good in the industry, outperforming 78.15% of the companies in the same industry.
A Debt/Equity ratio of 0.97 indicates that CADL is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.97, CADL is doing worse than 79.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF N/A
Altman-Z 4.32
ROIC/WACCN/A
WACC9.5%
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.59 indicates that CADL has no problem at all paying its short term obligations.
The Current ratio of CADL (2.59) is worse than 70.87% of its industry peers.
A Quick Ratio of 2.59 indicates that CADL has no problem at all paying its short term obligations.
With a Quick ratio value of 2.59, CADL is not doing good in the industry: 69.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.59
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

CADL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.43%.
Looking at the last year, CADL shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 13.14% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.88%
EPS Next 2Y13.14%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CADL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CADL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

CADL's earnings are expected to grow with 13.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.14%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CADL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANDEL THERAPEUTICS INC

NASDAQ:CADL (2/21/2025, 8:04:56 PM)

After market: 11.75 +0.12 (+1.03%)

11.63

-0.58 (-4.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2024-03-28/bmo
Earnings (Next)N/A N/A
Inst Owners51.6%
Inst Owner Change164.74%
Ins Owners18.61%
Ins Owner Change-31.85%
Market Cap513.23M
Analysts82.86
Price Target17.34 (49.1%)
Short Float %7.48%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-96.4%
Min EPS beat(2)-132.84%
Max EPS beat(2)-59.96%
EPS beat(4)1
Avg EPS beat(4)-49.23%
Min EPS beat(4)-132.84%
Max EPS beat(4)7.56%
EPS beat(8)4
Avg EPS beat(8)-14.45%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)72.73%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)11.21%
EPS NY rev (3m)-60.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 40.27
P/tB 40.27
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS0.29
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.1%
ROE -297.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.25%
ROA(5y)-44.18%
ROE(3y)-131.12%
ROE(5y)-96.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 2.59
Altman-Z 4.32
F-Score2
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)338.09%
Cap/Depr(5y)611.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.11%
EPS Next Y-9.88%
EPS Next 2Y13.14%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.85%
EBIT Next 3Y35.99%
EBIT Next 5Y55.1%
FCF growth 1Y-6.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.99%
OCF growth 3YN/A
OCF growth 5YN/A